KR20230051525A - 옥소피롤리딘 우레아 fpr2 효능제 - Google Patents
옥소피롤리딘 우레아 fpr2 효능제 Download PDFInfo
- Publication number
- KR20230051525A KR20230051525A KR1020237008160A KR20237008160A KR20230051525A KR 20230051525 A KR20230051525 A KR 20230051525A KR 1020237008160 A KR1020237008160 A KR 1020237008160A KR 20237008160 A KR20237008160 A KR 20237008160A KR 20230051525 A KR20230051525 A KR 20230051525A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- substituted
- hydrogen
- och
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063064640P | 2020-08-12 | 2020-08-12 | |
| US63/064,640 | 2020-08-12 | ||
| PCT/US2021/045474 WO2022035923A1 (en) | 2020-08-12 | 2021-08-11 | Oxopyrrolidine urea fpr2 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230051525A true KR20230051525A (ko) | 2023-04-18 |
Family
ID=77595649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237008160A Pending KR20230051525A (ko) | 2020-08-12 | 2021-08-11 | 옥소피롤리딘 우레아 fpr2 효능제 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12565483B2 (enExample) |
| EP (1) | EP4196471A1 (enExample) |
| JP (1) | JP7802765B2 (enExample) |
| KR (1) | KR20230051525A (enExample) |
| CN (1) | CN116057055B (enExample) |
| WO (1) | WO2022035923A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120957970A (zh) * | 2023-04-18 | 2025-11-14 | 百时美施贵宝公司 | 碳环苯基吡咯烷酮脲fpr2激动剂 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ752095A (en) | 2013-11-28 | 2022-07-01 | Kyorin Seiyaku Kk | Urea derivative or pharmacologically acceptable salt thereof |
| US10858314B2 (en) | 2015-05-27 | 2020-12-08 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
| US10525058B2 (en) | 2015-05-27 | 2020-01-07 | Kyorin Pharmaceutical Co., Ltd | Urea derivative or pharmacologically acceptable salt thereof |
| JP2018538367A (ja) | 2015-11-24 | 2018-12-27 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定 |
| KR102772801B1 (ko) * | 2015-12-10 | 2025-02-24 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| JP2020015664A (ja) * | 2016-11-21 | 2020-01-30 | 宇部興産株式会社 | 含窒素多環式ヘテロ環誘導体 |
| MX2019013926A (es) | 2017-05-22 | 2020-01-20 | Bristol Myers Squibb Co | Uso novedoso de un agonista del receptor 2 de formil peptido/receptor a4 de lipoxina (fpr2/alx) para el tratamiento de insuficiencia cardiaca. |
| CN110996950B (zh) | 2017-06-09 | 2023-04-04 | 百时美施贵宝公司 | 哌啶酮甲酰基肽2受体激动剂和甲酰基肽1受体激动剂 |
| ES2869129T3 (es) | 2017-06-09 | 2021-10-25 | Bristol Myers Squibb Co | Agonistas de piperidinona del receptor 2 de péptidos formilados |
| EP3634958B1 (en) * | 2017-06-09 | 2021-07-21 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| KR102615099B1 (ko) | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| SG11202008504SA (en) * | 2018-03-05 | 2020-10-29 | Bristol Myers Squibb Co | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| ES2964299T3 (es) * | 2018-11-26 | 2024-04-05 | Bristol Myers Squibb Co | Derivados de pirrolidinona como agonistas del receptor del péptido formilado 2 |
| ES2946673T3 (es) | 2019-06-18 | 2023-07-24 | Bristol Myers Squibb Co | Agonistas del FPR2 de óxido de biaril dialquil fosfina |
| JP7700210B2 (ja) | 2020-07-09 | 2025-06-30 | ブリストル－マイヤーズ スクイブ カンパニー | ピラゾロンホルミルペプチド２受容体アゴニスト |
| KR20230038515A (ko) | 2020-07-09 | 2023-03-20 | 브리스톨-마이어스 스큅 컴퍼니 | 옥소피롤리딘 fpr2 효능제 |
| KR20230084530A (ko) | 2020-10-09 | 2023-06-13 | 브리스톨-마이어스 스큅 컴퍼니 | 아미노이미다졸 fpr2 효능제 |
-
2021
- 2021-08-11 JP JP2023509739A patent/JP7802765B2/ja active Active
- 2021-08-11 US US18/040,831 patent/US12565483B2/en active Active
- 2021-08-11 WO PCT/US2021/045474 patent/WO2022035923A1/en not_active Ceased
- 2021-08-11 CN CN202180056346.1A patent/CN116057055B/zh active Active
- 2021-08-11 EP EP21763467.4A patent/EP4196471A1/en active Pending
- 2021-08-11 KR KR1020237008160A patent/KR20230051525A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023537410A (ja) | 2023-08-31 |
| CN116057055B (zh) | 2026-03-13 |
| EP4196471A1 (en) | 2023-06-21 |
| JP7802765B2 (ja) | 2026-01-20 |
| CN116057055A (zh) | 2023-05-02 |
| WO2022035923A1 (en) | 2022-02-17 |
| US20230303513A1 (en) | 2023-09-28 |
| US12565483B2 (en) | 2026-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102803660B1 (ko) | 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제 | |
| KR102772801B1 (ko) | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 | |
| KR102623473B1 (ko) | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 | |
| KR102953013B1 (ko) | 비아릴 디알킬 포스핀 옥시드 fpr2 효능제 | |
| CN116057055B (zh) | 氧代吡咯烷脲类fpr2激动剂 | |
| JP7771157B2 (ja) | オキソピロリジン ｆｐｒ２アゴニスト | |
| JP7700210B2 (ja) | ピラゾロンホルミルペプチド２受容体アゴニスト | |
| KR20230084530A (ko) | 아미노이미다졸 fpr2 효능제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20230308 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20240809 Comment text: Request for Examination of Application |